Medicine
from24/7 Wall St.
1 day agoIs Apellis Pharmaceuticals' FDA Win Just the Beginning?
Apellis faces a gap between regulatory approvals and commercial execution, with EMPAVELI's label promising rare-disease upside while SYFOVRE revenue and patient access lag.